Cliff Asness’s Avalo Therapeutics AVTX Stock Holding History

Cliff Asness’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-32	Closed	-$156K	–	2216
2021 Q4	$156K	Buy	32 +23	+256%	+$138K	﹤0.01%	2117
2021 Q3	$56K	Buy	+9	New	+$73K	﹤0.01%	2223

Other funds holding AVTX

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Cliff Asness's AVTX Position: Q1 2022 in Review

Cliff Asness sold out of Avalo Therapeutics (AVTX) in Q1 2022, closing a stake of 32 shares — an estimated $156K sold.

Cliff Asness first reported a position in AVTX in Q3 2021 and held it in 2 quarters. The position peaked at $156K in Q4 2021. 65 funds tracked by Wall St. Rank hold AVTX as of Q1 2022.

Cliff Asness reported no remaining Avalo Therapeutics position as of Q1 2022 after selling out during the quarter.
Cliff Asness sold 32 Avalo Therapeutics shares in Q1 2022, an estimated $156K.
Cliff Asness first reported a position in Avalo Therapeutics in Q3 2021 and held it in 2 quarters.
Cliff Asness's Avalo Therapeutics position peaked at $156K in Q4 2021.
65 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2022.

Based on AQR Capital Management's 13F filing for Q1 2022, filed 16 May 2022.